|By PR Newswire||
|August 8, 2014 07:00 AM EDT||
SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference in New York next week. The presentation is scheduled for Tuesday, August 12 at 12:45pm EDT.
The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's first drug product, Omidria™ (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omeros is completing preparations for an early fall 2014 U.S. product launch. Omidria is currently under review for marketing approval by the European Medicines Agency. Omeros' six clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.
SOURCE Omeros Corporation
Aug. 29, 2016 02:15 PM EDT Reads: 3,730
Aug. 29, 2016 02:00 PM EDT Reads: 952
Aug. 29, 2016 02:00 PM EDT Reads: 2,475
Aug. 29, 2016 01:01 PM EDT Reads: 203
Aug. 29, 2016 12:45 PM EDT Reads: 2,018
Aug. 29, 2016 12:15 PM EDT Reads: 815
Aug. 29, 2016 12:00 PM EDT Reads: 857
Aug. 29, 2016 12:00 PM EDT Reads: 3,187
Aug. 29, 2016 12:00 PM EDT Reads: 821
Aug. 29, 2016 08:15 AM EDT Reads: 738
Aug. 29, 2016 08:00 AM EDT Reads: 847
Aug. 29, 2016 08:00 AM EDT Reads: 938
Aug. 29, 2016 07:30 AM EDT Reads: 818
Aug. 29, 2016 03:00 AM EDT Reads: 2,429
Aug. 29, 2016 02:15 AM EDT Reads: 1,838